{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:50:04Z","timestamp":1774270204282,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The objective of this study was to assess the comparative safety profile (odds ratio) of ICIs and estimate the absolute rate of immune-related serious adverse events (irSAEs) in cancer patients undergoing treatment with ICIs. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched for randomized trials till February 2021, including all ICIs for all cancers. Primary outcome was overall irSAEs, and secondary outcomes were pneumonitis, colitis, hepatitis, hypophysitis, myocarditis, nephritis, and pancreatitis. We conducted Bayesian network meta-analyses, estimated absolute rates and ranked treatments according to the surface under the cumulative ranking curve (SUCRA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 96 trials (52,811 participants, median age 62\u00a0years). Risk of bias was high in most trials. Most cancers were non-small cell lung cancer (28 trials) and melanoma (15 trials). The worst-ranked ICI was ipilimumab (SUCRA 14%; event rate 848\/10,000 patients) while the best-ranked ICI was atezolizumab (SUCRA 82%; event rate 119\/10,000 patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Each ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03647-z","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T12:02:28Z","timestamp":1708344148000},"page":"677-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"given":"Clara","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Beatrice","family":"Mainoli","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo S.","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Rita G.","family":"Tinoco","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Esperan\u00e7a-Martins","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"3647_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga NA, Del Rincon SV, Papneja N, Miller WH (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:87\u201397. https:\/\/doi.org\/10.3747\/co.27.5223","journal-title":"Curr Oncol"},{"key":"3647_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxici-ty Management Working Group. J Immunother Cancer 5:1\u201328. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3647_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Medi-Cine 378(2):158\u201368","journal-title":"N Engl J Medi-Cine"},{"issue":"1","key":"3647_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/annonc\/mdx286","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JRC, Flores-Ch\u00e1vez MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primer Nat Res 6(1):38. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Nat Rev Dis Primer Nat Res"},{"key":"3647_CR5","first-page":"2377","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T et al (2017) Tumour- and class-specific patterns of immune-related adverse events of immune check-point inhibitors: A systematic review 28:2377\u20132385","journal-title":"Tumour- and class-specific patterns of immune-related adverse events of immune check-point inhibitors: a systematic review"},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"issue":"7","key":"3647_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2021","unstructured":"Sullivan RJ, Weber JS (2021) Immune-related toxicities of checkpoint inhibi-tors: mechanisms and mitigation strategies. Nat Rev Drug Discov Nat Res 21(7):495\u2013508. https:\/\/doi.org\/10.1038\/s41573-021-00259-5","journal-title":"Nat Rev Drug Discov Nat Res"},{"key":"3647_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y-P, Du X-J et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ 363:k4226","journal-title":"BMJ"},{"key":"3647_CR9","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons","DOI":"10.1002\/9781119536604"},{"key":"3647_CR10","unstructured":"Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Clinical Trials Transformation Initiative (CTTI). Available at: https:\/\/aact.ctti-clinicaltrials.org\/. Accessed: 11 Jul 2022"},{"key":"3647_CR11","unstructured":"ICH (1995) E2A - Clinical safety data management: Definitions and standards for expedited reporting"},{"issue":"2","key":"3647_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u201371","journal-title":"J Clin Epidemiol"},{"key":"3647_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"3647_CR14","first-page":"332","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ Online 339:332\u2013336","journal-title":"BMJ Online"},{"issue":"12","key":"3647_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"3647_CR16","unstructured":"Haanen JBAG, Lugowska I, Garassino MC, Califano R (2018) ESMO Handbook of Immuno-Oncology. ESMO Press"},{"key":"3647_CR17","unstructured":"European Commisision (2009) A Guideline on Summary of Product Characteristics (SmPC), Revision 2"},{"key":"3647_CR18","first-page":"511","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR et al (2019) Adverse events following cancer immunotherapy: obstacles and opportunities 40:511\u2013523","journal-title":"Adverse events following cancer immunotherapy: obstacles and opportunities"}],"updated-by":[{"DOI":"10.1007\/s00228-024-03732-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03647-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:03:42Z","timestamp":1721786622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03647-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03647-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00228-024-03732-3","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00228-024-03732-3","URL":"https:\/\/doi.org\/10.1007\/s00228-024-03732-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}